## Results for Dasatinib and Quercetin Senolytic Therapy Risk-Benefit Analysis

					1			
		New Articles False No.	legatives	<u>False Positives</u>				
Table 2: Estimated Relevance for False Negatives until 17. April, 2020 included in the Risk-Benefit Analysis but not classified as relevant.								
Relevance	Date	Title		Abstract		Expand	URL	
0.3	22. März, 2013	Bioavailability of quercetin: problems and promises		Quercetin (QC) is a typical plant flavonoid, possesses d		+	<u>pubmed</u>	
0.29	1. Januar, 2005	Cytotoxicity of flavonoids toward cultured normal hum		The cytotoxicity of flavonoids, including apigenin, erio		+	pubmed	
0.25	6. Februar, 2016	Association Between BCR-ABL Tyrosine Kinase Inhib		Importance: A phase 3 trial with ponatinib in patients		+	<u>pubmed</u>	
0.24	22. August, 2016					<u>-</u>	<u>clinicaltrials</u>	
		Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial (IPF)						
1		Abstract						
		The study team hypothesizes that intermittent (3 doses administered over 3 consecutive days in 3 consecutive						
i		weeks) oral administration of combination Dasatinib (100 mg/d) + Quercetin (1250 mg/d) will be safe and well						
1		tolerated in patients with IPF. Treatment with D+Q will result in reduced abundance of pro-inflammatory cells						
1		within subjects over baseline. Finally, the reduction in biomarkers of cellular pro-inflammatory state will be related to no change in functional and patient reported outcomes.						
i		related to no change in runctional and patient reported	1 Outcomes.					
0.22	10. Ianuar 2017	Identification of collular tangets involved in carding fail	Aime	The sime of the present study	to ovaluate t		nybmod	
0.22	19. Januar, 2017	Identification of cellular targets involved in cardiac fail	Alliis	:: The aims of the present study	were to evaluate t	+	<u>pubmed</u>	
0.22	3. Oktober, 2017	Short-term High Dose of Quercetin and Resveratrol Alt	Back	ground: Hyperglycemia-mediat	ed oxidative stress	+	<u>pubmed</u>	
0.22	14. Februar, 2018	BCR-ABL Tyrosine Kinase Inhibitors: Which Mechani	Imati	nib, the first-in-class BCR-ABI	L tyrosine kinase in	+	<u>pubmed</u>	
0.19	1. Januar, 2008	Quercetin pharmacokinetics in humans	The p	ourpose of this study was to exa	mine the pharmac	+	pubmed	
0.18	6. Mai, 2009	Tyrosine kinase inhibitor-induced platelet dysfunction i	Dasa	tinib is associated with increase	ed risk of bleeding	+	<u>pubmed</u>	
0.18	17. März, 2004	Quercetin, an over-the-counter supplement, causes neur	A 22	-month-old boy, who regularly o	consumed the oral	+	pubmed	
Page: <u>1</u> 2								

**Last updated:** Do 25. Feb 11:38:01 CET 2021